Αναζήτηση Δραστικών

VALSARTAN

ATC

Εμπορικές Ονομασίες

  • VELSA
    Μορφές: F.C.TAB
  • DIOVAN
    Μορφές: F.C.TAB
    Μορφές: ORAL.SOL
  • DALZAD
    Μορφές: F.C.TAB
  • DRUGBANK - Valsartan
  • indication:

    For the treatment of hypertension.

  • pharmacology:

  • mechanism:

    Valsartan competes with angiotensin II for binding at the AT<sub>1</sub> receptor subtype. As angiotensin II is a vasoconstrictor which also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decreases in systemic vascular resistance.

  • toxicity:

  • absorprion:

    Absolute bioavailability = 23% with high variability

  • halflife:

    The initial phase t<sub>1/2 α</sub> is < 1 hour while the terminal phase t<sub>1/2 β</sub> is 5-9 hours.

  • roouteelimination:

  • volumedistribution:

    * 17 L

  • clearance:

    * 2 L/h [IV administration] * 4.5 L/h [heart Failure patients receiving oral administration 40 to 160 mg twice a day]